Research
Hormonal
Race and geographic region significantly modify the risk of new-onset diabetes in people with HIV, with higher rates observed in South Asia and among Black or African American individuals in high-income regions.
If you are from South Asia or are Black/African American, you may have a higher baseline risk for diabetes. Work with your healthcare provider to monitor your blood sugar and weight closely, as these risks can be managed with lifestyle changes.
StrongSupportsHIGH confidence
DM incidence was highest in South Asia... In High Income GBD regions, higher rates of developing DM were seen among Black or African American PWH and those of ‘Other’ race.
Why this rating
Large global RCT with diverse population.
Source
Diabetes Risk Factors in People With HIV Receiving Pitavastatin Versus Placebo for Cardiovascular Disease Prevention
Kathleen V. Fitch et al. · Annals of Internal Medicine · 2024
DOI 10.7326/annals-24-00944
rct · n=7731Cited 6×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Pitavastatin 4mg daily increases the risk of new-onset diabetes in people with HIV, but this effect is clinically significant primarily in individuals with multiple baseline metabolic risk factors (obesity, pre-diabetes, or metabolic syndrome).Strong
- Baseline metabolic risk factors, specifically pre-diabetes, obesity (high BMI), and metabolic syndrome components, are the strongest predictors of new-onset diabetes in people with HIV, regardless of statin treatment.Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →